Treatment-resistant depression (TRD)

news

ECNP 2023: new esketamine NS safety data for depression

10 October 2023 | By Catherine Eckford (European Pharmaceutical Review)

New safety data for a Phase IIIb study in treatment-resistant depression (TRD), revealed at ECNC 2023, showed that esketamine NS significantly increased the proportion of patients achieving remission compared to quetiapine XR.

article

Leading in Pharma: a woman’s pathway

8 March 2023 | By Catherine Eckford (European Pharmaceutical Review), Dr Ekaterina Malievskaia (COMPASS Pathways)

Here, to mark International Women’s Day, Dr Ekaterina Malievskaia from COMPASS Pathways reveals her path to working in mental health and the pharma industry.

article

The potential of tryptamines in treatment-resistant depression

15 December 2022 | By Guy Goodwin (COMPASS Pathways)

There is growing interest in the use of psychedelic-assisted therapy for treatment of mental health conditions. Here, Guy Goodwin, Chief Medical Officer of COMPASS Pathways, explores the potential of tryptamines to treat depression, sharing results from a recent clinical trial.